Market revenue in 2022 | USD 2.8 million |
Market revenue in 2030 | USD 30.3 million |
Growth rate | 34.6% (CAGR from 2022 to 2030) |
Largest segment | C. difficile |
Fastest growing segment | C. difficile |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C. difficile, Crohns disease, Inflammatory Bowel Disease, Diabetes |
Key market players worldwide | Finch Therapeutics Group Inc, Vedanta |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to microbiome therapeutics market will help companies and investors design strategic landscapes.
C. difficile was the largest segment with a revenue share of 85.71% in 2022. Horizon Databook has segmented the Germany microbiome therapeutics market based on c. difficile, crohns disease, inflammatory bowel disease, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany microbiome therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Germany microbiome therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account